Director Jerry Griffin Sells Shares of Inspire Medical Systems Inc (INSP)
On March 11, 2024, Director Jerry Griffin executed a sale of 554 shares of Inspire Medical Systems Inc (NYSE:INSP), as reported in a recent SEC filing. The transaction resulted in the disposal of shares at a price of $198.05 each. Following this transaction, the insider's activity over the past year reflects a total sale of 7,431 shares and no recorded purchases of the company's stock.
Inspire Medical Systems Inc is a medical technology company focused on the development and commercialization of innovative solutions for patients with obstructive sleep apnea. The company's proprietary Inspire therapy is an FDA-approved treatment that works inside the body with a patient's natural breathing process to treat sleep apnea.
The insider transaction history at Inspire Medical Systems Inc shows a pattern of insider sales over the past year, with 20 insider sells and only 1 insider buy. This trend can be visualized in the following insider trend image:
As of the date of the insider's recent transaction, Inspire Medical Systems Inc had a market capitalization of $5.61 billion. The stock's price of $198.05 on the day of the sale, when compared to the GuruFocus Value (GF Value) of $448.50, indicates a price-to-GF-Value ratio of 0.44, suggesting that the company is significantly undervalued according to the GF Value metric. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is derived from historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates provided by Morningstar analysts.
The valuation of Inspire Medical Systems Inc based on its GF Value is illustrated in the image below:
The data provided offers an objective view of the insider's recent sale and the current valuation of Inspire Medical Systems Inc, without incorporating personal analysis or the use of adjectives.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
